Table 2.
Characteristics of symptoms and treatments prior to enrollment.
| Adolescent patients (N=42) |
Adult patients (N=178) |
Total patients (N=220) | |||||
|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | ||
| Duration of symptoms | |||||||
| <7 days | 8 | 19 | 25 | 14 | 33 | 15 | |
| 7–21 days | 18 | 43 | 98 | 55 | 116 | 53 | |
| >21 days | 16 | 38 | 54 | 31 | 70 | 32 | |
| Non-massive hemoptysis* | 4 | 10 | 25 | 14 | 29 | 13 | |
| Wheezing* | 2 | 5 | 35 | 20 | 37 | 17 | |
| Chest pain/pleurisy* | 7 | 17 | 45 | 26 | 52 | 24 | |
| PEx treated with IV antibiotics in the 6 months before enrollment | 13 | 31 | 82 | 46 | 95 | 43 | |
| Initial outpatient antibiotic therapy prior to enrollment* | 31 | 76 | 72 | 41 | 103 | 48 | |
*
Excluding missing data for failed outpatient treatment (n = 5), symptom duration (n = 1), hemoptysis (n = 2), wheezing (n = 4), and chest pain (n = 4)